Loss of MIR15A and MIR16‐1 at 13q14 is associated with increased TP53 <scp>mRNA</scp>, de‐repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia

doi:10.1111/bjh.13043

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Loss of MIR15A and MIR16‐1 at 13q14 is associated with increased TP53 <scp>mRNA</scp>, de‐repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia

18 Jul 2014

Abstract excerpt

This study was conducted to investigate the possibility that TP53 mRNA is variably expressed in chronic lymphocytic leukaemia (CLL) and that under-expression is associated with TP53 dysfunction and adverse outcome. Although TP53 mRNA levels did indeed vary among the 104 CLL samples examined, this variability resulted primarily from over-expression of TP53 mRNA in 18 samples, all of which lacked TP53...

Source

Open in PubMed

Identifiers

PMID: 25040181
DOI: 10.1111/bjh.13043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Loss of <i>MIR15A</i> and <i>MIR16‐1</i> at 13q14 is associated with increased <i>TP53 </i><scp>mRNA</scp>, de‐repression of <i>BCL2</i> and adverse outcome in chronic lymphocytic leukaemia

Abstract excerpt

Discuss the evidence